Attached files

file filename
EX-99.1 - EX-99.1 - CYTOKINETICS INCexhibit1.htm






Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):   November 26, 2012

Cytokinetics, Incorporated
(Exact name of registrant as specified in its charter)

Delaware 000-50633 94-3291317
(State or other jurisdiction
(I.R.S. Employer
of incorporation) File Number) Identification No.)
280 East Grand Avenue, South San Francisco, California   94080
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code:   (650) 624 - 3000

Not Applicable
Former name or former address, if changed since last report


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[  ]  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[  ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[  ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[  ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01 Other Events.

On November 26, 2012, Cytokinetics, Inc. issued a press release announcing positive data from a recently completed Phase IIa "Evidence of Effect" clinical trial of tirasemtiv in patients with generalized myasthenia gravis (MG). Tirasemtiv selectively activates the fast skeletal muscle troponin complex by increasing its sensitivity to calcium thereby increasing skeletal muscle force in response to neuronal input and delaying the onset and reducing the degree of muscle fatigue.

A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K, and is incorporated herein by reference.


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    Cytokinetics, Incorporated
November 26, 2012   By:   /s/ Sharon Barbari
        Name: Sharon Barbari
        Title: Executive Vice President, Finance and Chief Financial Officer

Exhibit Index

Exhibit No.   Description

  Press Release, dated November 26, 2012